The inflammatory storm in critically ill patients releases cytokines, causing systemic immune damage, which may be an important cause of multiple organ failure and even death. Inflammatory storms exacerbate the deterioration of the disease in those children. Gamma globulin may be an effective option to control inflammatory storms. However, this preliminary result needs to be verified from reliable and representative RCTs. In our study, we conducted a retrospective study on the use of gamma globulin and an unused control group. At present, the indications of IVIG are mainly focused on the neuromuscular system and the blood system. We hope to establish a more appropriate and operable evaluation table for the suitability of gamma globulin for clinical use.
In severe infective patients who survive the initial inflammatory storm, the immune response often evolves toward a state of immunosuppression, which contributes to increased mortality and severe secondary hospital-acquired infections. However, the role of gamma globulin therapy in patients with severe infection including sepsis and septic shock is discussed controversially. We intend to retrospectively analyze the efficacy and application evaluation of gamma globulin in severely infected children hospitalized in the intensive care unit. Clinical and demographic data, as well as treatment outcome will be collected from the electronic health record. It is expected to provide evaluation basis for clinicians to formulate treatment plans and clinical pharmacists for special comments on the clinical use of gamma globulin.
Study Type
OBSERVATIONAL
Enrollment
200
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China
RECRUITINGChildren's Hospital of Fudan University
Shanghai, China
RECRUITINGThe death rate of children
The death rate of children in 28 days after their discharged from PICU
Time frame: within 28 days after they discharged from PICU
length of stay in PICU
Time from PICU admission to discharge
Time frame: up to 28 days
CD4+/CD8+
levels of peripheral blood subgroup of T lymphocyte (digital form)
Time frame: Within 3 to 15 days after the start of treatment
C-reactive protein (CRP)
C-reactive protein (digital form)
Time frame: Within 3 to 15 days after the start of treatment
IL-2R
The interleukin-2 receptor (digital form)
Time frame: Within 3 to 15 days after the start of treatment
TNF-alpha
Tumor necrosis factor alpha (digital form)
Time frame: Within 3 to 15 days after the start of treatment
Treg
levels of peripheral blood subgroup of T lymphocyte (digital form)
Time frame: Within 3 to 15 days after the start of treatment
IL-6
The interleukin-6 (digital form)
Time frame: Within 3 to 15 days after the start of treatment
IFN-gamma
Interferon gamma (digital form)
Time frame: Within 3 to 15 days after the start of treatment
Procalcitonin (digital form)
Procalcitonin (digital form)
Time frame: Within 3 to 15 days after the start of treatment
IL-10
The interleukin-10 (digital form)
Time frame: Within 3 to 15 days after the start of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.